SCHEMBL7149329

SCHEMBL7149329

COC(=O)c1ccc(OC)cc1NC(C)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.54
HSD17B10 Q99714 2/20 0.54
GLA P06280 1/20 0.54
GAA P10253 1/20 0.54
HTT P42858 3/20 0.52
TSHR P16473 2/20 0.52
LMNA P02545 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
ALDH1A1 P00352 4/20 0.51
HPGD P15428 2/20 0.51
HSD17B1 P14061 1/20 0.51
HSD17B2 P37059 1/20 0.51
POLB P06746 1/20 0.51
PIK3CG P48736 1/20 0.50
MAPT P10636 1/20 0.49
AKR1C3 P42330 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6361641 0.87 AKR1C3 (0.65) AKR1C3AKR1C2
SCHEMBL14503735 0.84 HSD17B1 (0.57) KDM4EHSD17B10GLAGAAHTT
SCHEMBL26090331 0.83 KDM4E (0.71) KDM4EHSD17B10GLAGAATSHR
SCHEMBL1998117 0.81 RAB9A (0.51) KDM4EHTTTSHRLMNASMN1; SMN2
SCHEMBL30487008 0.81 KDM4E (0.69) KDM4EHSD17B10GLAGAALMNA
SCHEMBL13088436 0.81 KDM4E (0.69) KDM4EHSD17B10GLAGAALMNA
SCHEMBL12021288 0.81 SMN1; SMN2 (0.53) KDM4EHSD17B10GLAGAASMN1; SMN2
SCHEMBL16007784 0.81 HSD17B1 (0.47) KDM4EHSD17B10GLAGAAHTT
SCHEMBL2269238 0.80 KDM4E (0.68) KDM4EHSD17B10GAAHTTTSHR
SCHEMBL27969573 0.80 KDM4E (0.49) KDM4EHSD17B10GLAGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023066359-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. (US) 2023-04-27 WO disclosed
US-6528528-B2 Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis CONNOR DAVID THOMAS (US) 2001-10-18 US disclosed
US-6268387-B1 INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. WARNER-LAMBERT COMPANY 2001-07-31 US disclosed
EP-1042276-A1 THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY LLC (US) 2000-10-11 EP disclosed
WO-1999032433-A1 THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis TPMT, CTH, CBS KDM4E 3150/4885HSD17B10 2178/4885GLA 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.